Close Menu

NEW YORK (GenomeWeb) – Epic Sciences and Genomic Health said today that Medicare contractor Palmetto GBA has issued a draft local coverage determination (LCD) for the Oncotype DX AR-V7 Nucleus Detect test.

The companies said that if finalized, the LCD would extend coverage of the test to 25,000 Medicare patients with advanced prostate cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
13
Sponsored by
Beckman Coulter Life Sciences

Mitigation of the SARS-CoV-2 pandemic will continue to require innovative solutions. This webinar will outline how Fry Laboratories rapidly redeployed a next-generation sequencing (NGS) pipeline originally created for the detection and identification of bacterial, eukaryotic, and fungal infections in response to SARS-CoV-2.

Apr
16
Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.